99 related articles for article (PubMed ID: 17932340)
1. The use of FoxP3 as a biomarker and prognostic factor for malignant human tumors.
Schreiber TH
Cancer Epidemiol Biomarkers Prev; 2007 Oct; 16(10):1931-4. PubMed ID: 17932340
[TBL] [Abstract][Full Text] [Related]
2. Human FOXP3 and cancer.
Martin F; Ladoire S; Mignot G; Apetoh L; Ghiringhelli F
Oncogene; 2010 Jul; 29(29):4121-9. PubMed ID: 20498631
[TBL] [Abstract][Full Text] [Related]
3. Identification of CD8+CD25+Foxp3+ suppressive T cells in colorectal cancer tissue.
Chaput N; Louafi S; Bardier A; Charlotte F; Vaillant JC; Ménégaux F; Rosenzwajg M; Lemoine F; Klatzmann D; Taieb J
Gut; 2009 Apr; 58(4):520-9. PubMed ID: 19022917
[TBL] [Abstract][Full Text] [Related]
4. Identification and characterization of Foxp3(+) gammadelta T cells in mouse and human.
Kang N; Tang L; Li X; Wu D; Li W; Chen X; Cui L; Ba D; He W
Immunol Lett; 2009 Aug; 125(2):105-13. PubMed ID: 19539651
[TBL] [Abstract][Full Text] [Related]
5. The regulatory T cell-associated transcription factor FoxP3 is expressed by tumor cells.
Ebert LM; Tan BS; Browning J; Svobodova S; Russell SE; Kirkpatrick N; Gedye C; Moss D; Ng SP; MacGregor D; Davis ID; Cebon J; Chen W
Cancer Res; 2008 Apr; 68(8):3001-9. PubMed ID: 18413770
[TBL] [Abstract][Full Text] [Related]
6. Targeting CD4+CD25+FoxP3+ regulatory T-cells for the augmentation of cancer immunotherapy.
Schabowsky RH; Madireddi S; Sharma R; Yolcu ES; Shirwan H
Curr Opin Investig Drugs; 2007 Dec; 8(12):1002-8. PubMed ID: 18058571
[TBL] [Abstract][Full Text] [Related]
7. Smad3 and NFAT cooperate to induce Foxp3 expression through its enhancer.
Tone Y; Furuuchi K; Kojima Y; Tykocinski ML; Greene MI; Tone M
Nat Immunol; 2008 Feb; 9(2):194-202. PubMed ID: 18157133
[TBL] [Abstract][Full Text] [Related]
8. Quantitative DNA methylation analysis of FOXP3 as a new method for counting regulatory T cells in peripheral blood and solid tissue.
Wieczorek G; Asemissen A; Model F; Turbachova I; Floess S; Liebenberg V; Baron U; Stauch D; Kotsch K; Pratschke J; Hamann A; Loddenkemper C; Stein H; Volk HD; Hoffmüller U; Grützkau A; Mustea A; Huehn J; Scheibenbogen C; Olek S
Cancer Res; 2009 Jan; 69(2):599-608. PubMed ID: 19147574
[TBL] [Abstract][Full Text] [Related]
9. Incidence and prognostic impact of FoxP3+ regulatory T cells in human gliomas.
Heimberger AB; Abou-Ghazal M; Reina-Ortiz C; Yang DS; Sun W; Qiao W; Hiraoka N; Fuller GN
Clin Cancer Res; 2008 Aug; 14(16):5166-72. PubMed ID: 18698034
[TBL] [Abstract][Full Text] [Related]
10. The presence of tumor-infiltrating FOXP3+ lymphocytes correlates with intratumoral angiogenesis in endometrial cancer.
Giatromanolaki A; Bates GJ; Koukourakis MI; Sivridis E; Gatter KC; Harris AL; Banham AH
Gynecol Oncol; 2008 Aug; 110(2):216-21. PubMed ID: 18533240
[TBL] [Abstract][Full Text] [Related]
11. GATA3-driven Th2 responses inhibit TGF-beta1-induced FOXP3 expression and the formation of regulatory T cells.
Mantel PY; Kuipers H; Boyman O; Rhyner C; Ouaked N; Rückert B; Karagiannidis C; Lambrecht BN; Hendriks RW; Crameri R; Akdis CA; Blaser K; Schmidt-Weber CB
PLoS Biol; 2007 Dec; 5(12):e329. PubMed ID: 18162042
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic targeting of FOXP3-positive regulatory T cells using a FOXP3 peptide vaccine WO2008081581.
Banham AH; Pulford K
Expert Opin Ther Pat; 2009 Jul; 19(7):1023-8. PubMed ID: 19456276
[TBL] [Abstract][Full Text] [Related]
13. Special regulatory T-cell review: FOXP3 biochemistry in regulatory T cells--how diverse signals regulate suppression.
Li B; Greene MI
Immunology; 2008 Jan; 123(1):17-9. PubMed ID: 18154614
[TBL] [Abstract][Full Text] [Related]
14. A low number of tumor-infiltrating FOXP3-positive cells during primary systemic chemotherapy correlates with favorable anti-tumor response in patients with breast cancer.
Aruga T; Suzuki E; Saji S; Horiguchi S; Horiguchi K; Sekine S; Kitagawa D; Funata N; Toi M; Sugihara K; Kuroi K
Oncol Rep; 2009 Aug; 22(2):273-8. PubMed ID: 19578766
[TBL] [Abstract][Full Text] [Related]
15. Transcriptional regulation of Foxp3 gene: multiple signal pathways on the road.
Shen Z; Chen L; Hao F; Wu J
Med Res Rev; 2009 Sep; 29(5):742-66. PubMed ID: 19267400
[TBL] [Abstract][Full Text] [Related]
16. Forkhead box protein 3: essential immune regulatory role.
Nik Tavakoli N; Hambly BD; Sullivan DR; Bao S
Int J Biochem Cell Biol; 2008; 40(11):2369-73. PubMed ID: 18037337
[TBL] [Abstract][Full Text] [Related]
17. CD4(+)CD25(+)CD127(low/-) regulatory T cells express Foxp3 and suppress effector T cell proliferation and contribute to gastric cancers progression.
Shen LS; Wang J; Shen DF; Yuan XL; Dong P; Li MX; Xue J; Zhang FM; Ge HL; Xu D
Clin Immunol; 2009 Apr; 131(1):109-18. PubMed ID: 19153062
[TBL] [Abstract][Full Text] [Related]
18. Forced overexpression of either of the two common human Foxp3 isoforms can induce regulatory T cells from CD4(+)CD25(-) cells.
Aarts-Riemens T; Emmelot ME; Verdonck LF; Mutis T
Eur J Immunol; 2008 May; 38(5):1381-90. PubMed ID: 18412171
[TBL] [Abstract][Full Text] [Related]
19. Nonfunctional regulatory T cells and defective control of Th2 cytokine production in natural scurfy mutant mice.
Lahl K; Mayer CT; Bopp T; Huehn J; Loddenkemper C; Eberl G; Wirnsberger G; Dornmair K; Geffers R; Schmitt E; Buer J; Sparwasser T
J Immunol; 2009 Nov; 183(9):5662-72. PubMed ID: 19812199
[TBL] [Abstract][Full Text] [Related]
20. Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer.
Salama P; Phillips M; Grieu F; Morris M; Zeps N; Joseph D; Platell C; Iacopetta B
J Clin Oncol; 2009 Jan; 27(2):186-92. PubMed ID: 19064967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
